A Study of Secondary Cytoreductive Therapy in Platinum-Sensitive Ovarian Cancer
Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a randomized controlled phase II study to evaluate secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité Universitatsmedizin Berlin, discusses a randomized controlled phase II study to evaluate secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
In this randomized trial, patients with platinum-sensitive ovarian cancer were randomized to surgery followed by chemotherapy or chemotherapy alone. The interim analysis showed a clear significant benefit in progression-free survival with surgery followed by chemotherapy. Investigators are now waiting for overall survival data, which they hope will be mature by 2019.
